Related Experiment Video
Updated: Mar 29, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
24.8K
Hepatitis C Virus: Current and Evolving Treatments for Genotype 4
Tarik Asselah1, Marc Bourlière2
1Department of Hepatology, Beaujon Hospital, UNITY, INSERM, UMR1149, Team Viral hepatitis, Centre de Recherche sur l'inflammation, Labex INFLAMEX, Université Denis Diderot Paris 7, 100 Bd du Général Leclerc, Clichy, Cedex 92110, France.
Gastroenterology Clinics of North America
|November 25, 2015
Summary
Direct-acting antivirals (DAAs) offer effective, short-term treatments for Hepatitis C virus (HCV) genotype 4. This review covers managing HCV genotype 4 infections with modern DAA regimens.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) affects over 170 million globally, causing chronic liver disease.
- HCV genotype 4 is prevalent in the Middle East and Africa, with recent spread to Europe.
- Direct-acting antivirals (DAAs) have revolutionized HCV treatment.
Purpose of the Study:
- To review the management of chronic Hepatitis C virus genotype 4.
- To discuss the application of direct-acting antivirals (DAAs) in HCV genotype 4 treatment.
- To highlight current therapeutic strategies in the DAA era.
Main Methods:
- Literature review of studies on HCV genotype 4.
- Analysis of clinical trial data for direct-acting antiviral regimens.
- Synthesis of current guidelines and expert opinions on HCV management.
Main Results:
- DAA regimens demonstrate high efficacy and short treatment durations for HCV genotype 4.
- Interferon-free treatments offer favorable safety profiles.
- Multiple DAA combinations are available, with or without ribavirin.
Conclusions:
- DAAs represent a significant advancement in treating HCV genotype 4.
- Current management focuses on highly effective and well-tolerated DAA-based therapies.
- Optimal treatment selection depends on patient factors and regimen availability.
Keywords:
Access to treatmentDirect-acting antiviralsEgyptLedipasvirOmbitasvirParitaprevirScreeningSofosbuvirMore Related Videos
Related Concept Videos
01:25Hepatitis
37
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
37
01:30Inhibitors of Viral Protein Synthesis
24
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
24
01:10Retrovirus Life Cycles
50.6K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.6K
01:28Pneumonia IV: Management
1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K